生化科技研發業
暫不提供
60人
台北市南港區忠孝東路七段508號12樓
育世股為楊育民博士及蕭世嘉博士在2017年共同創立。董事長楊育民博士曾在Genentech、Juno Therapeutics等大藥廠擔任執行副總裁,具數十年跨國藥廠管理經驗。執行長蕭世嘉博士為青年創業家,其核心技術——抗體細胞連結(Antibody-Cell Conjugation,ACC),衍生自2022年諾貝爾化學獎得主、美國史丹佛大學Carolyn Bertozzi教授的點擊化學(click chemistry)生物正交化學(bioorthogonal chemistry)研究,其也為此技術的共同發明人之一。 育世博專注研發新世代的細胞免疫療法,針對實體腫瘤及血液腫瘤等未滿足醫療需求,應用ACC 技術平台,發展出一系列「異體」的抗體連結免疫細胞 (Antibody-Conjugated Effector cells, ACE) 產品,且產品因「可凍存」,故同時具備「現成型 (off-the-shelf)」之優勢。除上述ACC技術平台業已獲得多國專利外,育世博自行開發出具有CD16表面抗原表現,且對腫瘤細胞有較強毒殺能力的自然殺手細胞oNK,亦已取得PCT專利。目前育世博同步也完成另一個細胞平台gamma delta T 細胞的開發,透過ACC 技術平台,發展出接續的產品,對於腫瘤的毒發發揮絕佳的效果。 目前公司已有多項細胞治療新藥進入臨床階段:首件自然殺手細胞治療新藥ACE1702,目標適應症為HER2表現實體腫瘤; 接續的ACE1831與ACE2016,係針對CD20表現血液腫瘤與EGFR表現實體腫瘤之gamma delta T細胞新藥,皆於台灣與美國同步進行一期臨床試驗,公司也籌畫將細胞新藥應用於自體免疫疾病上的治療。 Acepodia was founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche, and Genentech, and by Dr. Sonny Hsiao, UC Berkeley Cell Biologist and one of the inventors of Acepodia’s core technology, which is derived from the research on click chemistry and bioorthogonal chemistry by the 2022 Nobel Prize winner in Chemistry, Professor Carolyn Bertozzi of Stanford University. Dr. Hsiao is also one of the co-inventors of this technology. Acepodia is a pubilc biotechnology company focused on developing novel, targeted, allogeneic cell therapies to treat cancers. Acepodia is employing a flexible therapeutic design that leverages cutting-edge technologies to develop the next generation of off-the-shelf cell therapies by supercharging select oNK cells and gamma delta (γδ) T cells to target and engage cancer cells. Our approach is based on developing the most potent immune cells possible and equipping them with the optimal cellular targeting mechanisms needed to engage cancer cells with proprietary platform technologies. By arming our powerful cancer-killing cells with our tumor-targeting technology, Antibody-Cell Conjugation (ACC), Acepodia believes it can develop powerful, accessible cell therapies for patients with cancer. Acepodia has already advanced several cell therapy candidate programs into the clinical stage: The first is ACE1702, , a HER2-targeting NK cell therapy candidate. Following that are ACE1831 and ACE2016, gamma delta T cell therapies aimed at CD20-expressing hematological tumors and EGFR-expressing solid tumors, respectively. These drugs are undergoing Phase I clinical trials simultaneously in Taiwan and the United States. The company is also expanding the application of cell therapy drugs to the treatment of autoimmune diseases and is currently planning to apply for a Phase I clinical trial with the U.S. FDA.
ACC(Antibody-Cell Conjugation) 、NKselect、gdTselect platform ,發展抗體接合免疫細胞(Antibody-Conjugated Effector cells, AC),應用於癌症治療新藥開發
1. 員工團保(醫療/壽險/意外險) 2. 優於勞基法之特休假 3. 30天全薪病假 4. 員工外訓補助 5. 每年健康檢查補助 6. 婚喪喜慶禮金